NCT01023321View on ClinicalTrials.gov

First-in-Human Single Ascending and Multiple Dose of GLPG0555

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

April 30, 2010

Study Completion Date

May 31, 2010

Conditions
Healthy
Interventions
DRUG

GLPG0555

single ascending doses, oral solution

DRUG

placebo

single dose, oral solution

DRUG

GLPG0555

multiple dose, oral solution, 7 or 14 days

DRUG

placebo

multiple dose, oral solution, 7 or 14 days

Trial Locations (1)

Unknown

SGS Stuivenberg, Antwerp

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT01023321 - First-in-Human Single Ascending and Multiple Dose of GLPG0555 | Biotech Hunter | Biotech Hunter